Explore

Trendline Trendline
Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Progress
Trendline Trendline
D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types

D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types

D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types
Trendline Trendline
Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies

Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies

Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies
Trendline Trendline
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins to Advance Cancer Vaccine Platform

Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins to Advance Cancer Vaccine Platform

Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins to Advance Cancer Vaccine Platform
Trendline Trendline
D3 Bio's KRAS Inhibitor Shows Promising Results in Phase 2 Trials for Multiple Tumors

D3 Bio's KRAS Inhibitor Shows Promising Results in Phase 2 Trials for Multiple Tumors

D3 Bio's KRAS Inhibitor Shows Promising Results in Phase 2 Trials for Multiple Tumors
Trendline Trendline
Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology
Trendline Trendline
Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026

Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026

Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026
Trendline Trendline
Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma
Trendline Trendline
Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data

Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data

Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data
Trendline Trendline
AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal
Trendline Trendline
Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility
Trendline Trendline
Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026